サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：菌状息肉症の世界市場－成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1149073

菌状息肉症の世界市場－成長、将来展望、競合分析（2022年～2030年）

Mycosis Fungoides Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
菌状息肉症の世界市場－成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月11日
発行: Acute Market Reports
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の菌状息肉症の市場規模は、2022年から2030年の予測期間中に4.9％のCAGRで成長すると予想されています。菌状息肉症の発生率の上昇、USFDAが規定する厳しい治療ガイドライン、希少疾病の治療に対する政府の積極的な政策は、菌状息肉症市場の成長を促進しています。

当レポートでは、世界の菌状息肉症市場について調査分析し、ビジネス展望、市場力学、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象者
    • 主な製品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ－2次調査
    • フェーズⅡ－1次調査
    • フェーズⅢ－専門家による審査
    • 仮定
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界の菌状息肉症市場
  • 世界の菌状息肉症市場（100万米ドル）（2021年）：治療別
  • 世界の菌状息肉症市場（100万米ドル）：地域別
  • COVID-19の影響
  • 魅力的な投資提案（2021年）：地域別
  • 競合分析
    • 主要な菌状息肉症市場ベンダーの市場ポジショニング
    • 菌状息肉症市場のベンダーが採用する戦略
    • 主要な業界戦略

第3章 菌状息肉症市場：ビジネス展望と市場力学

  • イントロダクション
  • 世界の菌状息肉症市場金額（100万米ドル）（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
    • サプライヤーの力
    • バイヤーの力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治的
    • 経済的
    • 技術的
    • 法的
    • 社会的

第4章 菌状息肉症市場、米ドル（100万）（2020年～2030年）：治療別

  • 市場概要
  • 成長と収益分析：2021年と2030年の比較
  • 市場セグメンテーション
    • 局所ステロイド
    • メクロレタミンゲル
    • HDAC阻害剤
    • モノクローナル抗体
    • 局所放射線療法
    • 体外フォトフェレーシス
    • その他

第5章 北米の菌状息肉症市場、米ドル（100万）（2020年～2030年）

第6章 英国および欧州連合の菌状息肉症市場、米ドル（100万）（2020年～2030年）

第7章 アジア太平洋の菌状息肉症市場、米ドル（100万）（2020年～2030年）

第8章 ラテンアメリカ菌状息肉症市場、米ドル（100万）（2020年～2030年）

第9章 中東およびアフリカ菌状息肉症市場、米ドル（100万）（2020年～2030年）

第10章 企業プロファイル

  • Astellas Pharma
  • Bayer AG
  • Dover Medical and Scientific Equipment, Ltd.
  • Elorac, Inc.
  • Kyowa Kirin, Inc.
  • Macopharma
  • Sanofi SA
  • Soligenix, Inc.
  • Varian Medical Systems
  • Yaupon Therapeutics
図表

List of Tables

  • TABLE 1 Global Mycosis Fungoides Market By Treatment, 2020-2030, USD (Million)
  • TABLE 2 North America Mycosis Fungoides Market By Treatment, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Mycosis Fungoides Market By Treatment, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Mycosis Fungoides Market By Treatment, 2020-2030, USD (Million)
  • TABLE 5 Latin America Mycosis Fungoides Market By Treatment, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Mycosis Fungoides Market By Treatment, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Mycosis Fungoides Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Mycosis Fungoides Market: Quality Assurance
  • FIG. 5 Global Mycosis Fungoides Market, By Treatment, 2021
  • FIG. 6 Global Mycosis Fungoides Market, By Geography, 2021
  • FIG. 7 Global Mycosis Fungoides Market, By Treatment, 2021 Vs 2030, %
  • FIG. 8 U.S. Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 15 France Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 17 China Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 19 India Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Mycosis Fungoides Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Mycosis Fungoides Market (US$ Million), 2020 - 2030
目次
Product Code: 136748-08-22

Industry Outlook

The mycosis fungoides market is set to project sublime growth at a compounded annual growth rate (CAGR) of 4.9% during the forecast period from 2022 to 2030. Mycosis fungoides occurs in 70% of the patients suffering with cutaneous T cell lymphoma (CTCL), affecting initially to the skin later the infection spreads to internal organs in the later stages of the disease. Currently combinatorial treatment regimen is employed by oncologist worldwide to subdue the clinical manifestation occurring during the course of disease. SGX301 (Soligenix, Inc.) and 0.5% naloxone hydrochloride lotion (Elorac, Inc.) are currently in the phase III clinical trials being studied for its safety and efficacy for the treatment of mycosis fungoides.

"Recent USFDA approval of Poteligeo for the treatment of mycosis fungoides will increase the demand for monoclonal antibodies treatment regime"

As per the new guidelines formulated by National Comprehension Cancer Network (NCCN), there is no permanent cure for mycosis fungoides. The treatment regimen comprises of individual and combinatorial therapy depending upon the stage and severity of the disease. Usually topical steroids and mechlorethamine gel are used as a topical treatment in the early stage of the disease, if need be localized radiation therapy is also recommended by oncologist depending upon the spread of mycosis fungoides. HDAC inhibitors and extracorporeal photopheresis are prescribed to patients in stage 2 of the disease. Monoclonal antibodies are given by systemic circulation during the late stages of mycosis fungoides. Recent approval by USFDA for Poteligeo (mogamulizumab) will further boost the demand for monoclonal antibodies as the first line of treatment for mycosis fungoides during the forecast period.

"Rising incidence of mycosis fungoides and stringent treatment guidelines stipulated by USFDA drive the market growth in North America"

North America is presently ruling the regional segment for mycosis fungoides market representing a share of 31.8%. The parameters responsible for its impressive market growth are rising incidence of mycosis fungoides and stringent treatment guidelines stipulated by USFDA. The National Institute of Health (NIH), has reported the prevalence rate of mycosis fungoides in United States is ranging from 3 to 6 per 100,000 people annually. The presence of major players such as Sanofi S.A., Astellas Pharma, Soligenix, Inc., Yaupon Therapeutics etc. further bolster the market growth in North America region. Europe is in the second place holding a market share of 28.4% primarily due to favorable reimbursement scenario pertaining to treatment of mycosis fungoides in EU region. Strategic collaboration between biopharmaceutical companies and academic research institutes further strengthen the market growth in European region. Asia Pacific with a market share of 16.2% is keen to register rapid growth on account of supportive regulatory environment provided by the local healthcare agencies and proactive government policies to treat orphan and rare diseases.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Mycosis Fungoides market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Mycosis Fungoides market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Treatment

Topical Steroids

Mechlorethamine Gel

HDAC Inhibitors

Monoclonal Antibodies

Localized Radiation Therapy

Extracorporeal Photopheresis

Others

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Mycosis Fungoides market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Mycosis Fungoides market?

Which is the largest regional market for Mycosis Fungoides market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Mycosis Fungoides market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Mycosis Fungoides market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Mycosis Fungoides Market
  • 2.2. Global Mycosis Fungoides Market, By Treatment, 2021 (US$ Million)
  • 2.3. Global Mycosis Fungoides Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Mycosis Fungoides Market Vendors
    • 2.6.2. Strategies Adopted by Mycosis Fungoides Market Vendors
    • 2.6.3. Key Industry Strategies

3. Mycosis Fungoides Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Mycosis Fungoides Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Mycosis Fungoides Market: By Treatment, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Topical Steroids
    • 4.3.2. Mechlorethamine Gel
    • 4.3.3. HDAC Inhibitors
    • 4.3.4. Monoclonal Antibodies
    • 4.3.5. Localized Radiation Therapy
    • 4.3.6. Extracorporeal Photopheresis
    • 4.3.7. Others

5. North America Mycosis Fungoides Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Mycosis Fungoides Market: By Treatment, 2020-2030, USD (Million)
  • 5.3.Mycosis Fungoides Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Mycosis Fungoides Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Mycosis Fungoides Market: By Treatment, 2020-2030, USD (Million)
  • 6.3.Mycosis Fungoides Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Mycosis Fungoides Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Mycosis Fungoides Market: By Treatment, 2020-2030, USD (Million)
  • 7.3.Mycosis Fungoides Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Mycosis Fungoides Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Mycosis Fungoides Market: By Treatment, 2020-2030, USD (Million)
  • 8.3.Mycosis Fungoides Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Mycosis Fungoides Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Mycosis Fungoides Market: By Treatment, 2020-2030, USD (Million)
  • 9.3.Mycosis Fungoides Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Astellas Pharma
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Bayer AG
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. Dover Medical and Scientific Equipment, Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. Elorac, Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Kyowa Kirin, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Macopharma
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Sanofi SA
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Soligenix, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Varian Medical Systems
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Yaupon Therapeutics
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives